The Heat Shock Factor Protein 1 pipeline drugs market research report outlays comprehensive information on the Heat Shock Factor Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Heat Shock Factor Protein 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, Infectious Disease, and Metabolic Disorders which include the indications Breast Cancer, Prostate Cancer, Parkinson’s Disease, Friedreich Ataxia, Unspecified Viral Infections, Unspecified Fungal Infections, Obesity, and Type 2 Diabetes. It also reviews key players involved in Heat Shock Factor Protein 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Heat Shock Factor Protein 1 pipeline targets constitutes close to 11 molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, and Discovery stages are 1, 5, and 4 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Heat Shock Factor Protein 1 overview
Heat shock factor protein 1 (HSF1) is a transcription factor that is rapidly induced after temperature stress. It functions as a stress-inducible and DNA-binding transcription factor that plays a central role in the transcriptional activation of the heat shock response (HSR), leading to the expression of a large class of molecular chaperones, heat shock proteins (HSPs), that protect cells from cellular insult damage.
For a complete picture of Heat Shock Factor Protein 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
